Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Liraglutide And Semaglutide Market?

Over the past few years, the market size for liraglutide and semaglutide has seen a swift escalation. It is projected to expand from $15.19 billion in 2024 to $16.94 billion in 2025, indicating a compound annual growth rate (CAGR) of 11.5%. The significant growth during the previous periods can be traced back to the growing occurrence of diabetes, an increase in obesity-related diseases, amplification in the number of clinical trials, enhanced investment in diabetes research and developmental endeavors, as well as the heightened demand for easily accessible treatment methods.

There is a forecast of a swift expansion in the liraglutide and semaglutide market in the approaching years, with the market predicted to rise to $26.07 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 11.4%. The anticipated growth can be attributed to the increasing acceptance of GLP-1 receptor agonists, the expansion in healthcare spending, growth in product portfolios of pharmaceutical companies, elevation in disposable income, and a growing elderly population vulnerable to diabetes. Key trends for the forecast period encompass the incorporation of digital health platforms, the execution of personalized dosing methods, progress in drug delivery technologies, the creation of biosimilar versions, and the inclusion of artificial intelligence in treatment decision-making processes.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18400&type=smp

What Core Drivers Are Expected To Influence The Liraglutide And Semaglutide Market?

The escalating count of diabetes sufferers is predicted to fuel the expansion of the liraglutide and semaglutide markets. Diabetes, a chronic disease, is distinguished by high blood sugar levels due to the body’s resistance to insulin and inadequate insulin production. Sedentary habits, unhealthy eating, and genetic factors are leading to an increase in the diabetic populace. Both liraglutide and semaglutide play a crucial role in diabetes treatment, providing successful control of blood sugar levels and lowering the chances of diabetes-related complications. For example, data from the National Health Service, a government agency in the UK, show that in 2023, the NHS identified an extra 549,000 individuals in England who are at the verge of developing type 2 diabetes. This implies a significant uptick from the 3,065,825 recorded in 2022, signaling a rise of nearly 20%, taking the total number of non-diabetic people with hyperglycemia registered with a GP to 3,615,330. Thus, the growing diabetic population is a driving force for the liraglutide and semaglutide markets.

What Are The Main Segment Classifications In The Liraglutide And Semaglutide Market?

The liraglutide and semaglutidemarket covered in this report is segmented –

1) By Type: Pills; Liquid

2) By Administration: Parenteral; Oral

3) By Application: Type 2 Diabetes Mellitus; Obesity; Other Applications

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Pills: Oral Tablets (Liraglutide, Semaglutide); Extended-Release Oral Formulations

2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide); Pre-Filled Syringes; Vials For Injection

Which Emerging Trends Are Reshaping The Liraglutide And Semaglutide Market Landscape?

Leading businesses in the liraglutide and semaglutide markets are making strides in the production of anti-diabetic biosimilar drugs. These drugs serve to increase glucose regulation and diminish cardiovascular hazards in individuals with diabetes. These highly efficient and less costly biosimilars act as near-exact replicas of the original diabetes biologics, providing the same health advantages. For example, in January 2024, Glenmark Pharmaceuticals Ltd., a pharmaceutical corporation located in India, introduced a biosimilar for the well-known anti-diabetic medication, Liraglutide, to the Indian market for the first time. This is a parallel of Liraglutide, designed to enhance glycemic control in adults afflicted with type 2 diabetes mellitus. The release of such a drug significantly mitigates the cost of daily treatment, thereby making it more accessible to a wider range of patients across the nation. With an average price of about INR 100 for a usual 1.2 mg dosage per day, the cost of treatment is slashed by roughly 70% and a doctor’s prescription is necessary in order to obtain it.

Which Companies Are Contributing Significantly To The Liraglutide And Semaglutide Market Growth?

Major companies operating in the liraglutide and semaglutide market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Pharma Co. Ltd., Shionogi & Co. Ltd., Cadila Pharmaceuticals, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Biocon, Glenmark Pharmaceuticals Ltd., Bachem, Zealand Pharma, Shenzhen JYMed Technology Co. Ltd., Incepta Pharmaceuticals Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report

Which Region Holds The Greatest Opportunity For Liraglutide And Semaglutide Market Expansion?

North America was the largest region in the liraglutide and semaglutide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=18400&type=smp

Browse Through More Reports Similar to the Global Liraglutide And Semaglutide Market 2025, By The Business Research Company

Gluten Free Food Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gluten-free-food-global-market-report

Glutamic Acid Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glutamic-acid-global-market-report

Self Monitoring Blood Glucose Smbg Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/self-monitoring-blood-glucose-smbg-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model